Uncategorized

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

Published

on

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version